GMED · Investment summary · as of 4 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
At $81.47, GMED requires a 6% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 9%.
The disagreement with the market is about whether the ORGANIC growth rate is 8.5% or ~5%, not about the terminal margin - the margin axis carries 5.02pp of slack (20.0% assumed against 14.98% required) and holds its sign even at the un-normalised TTM margin, whereas the growth axis is what the impairment case attacks and what the two-year organic stack of 5.65% calls into question.
The value rests on an exit multiple of 13.1x, a terminal operating margin of 20% and a 8.2% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: NAMED CAUSE, not a valuation bear case.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market is about whether the ORGANIC growth rate is 8.5% or ~5%, not about the terminal margin - the margin axis carries 5.02pp of slack (20.0% assumed against 14.98% required) and holds its sign even at the un-normalised TTM margin, whereas the growth axis is what the impairment case attacks and what the two-year organic stack of 5.65% calls into question. |
| What do we forecast? | Revenue growth of 9% demonstrated; a terminal operating margin of 20%; an exit multiple of 13.1x. |
| What does Street forecast? | Not determined — no consensus figures are on file |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +2.3 percentage points. |
| What is it worth? | Twelve-month target $94.50, +16% from the struck price. Scenario-weighted expected return net of costs +16.0%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| quarterly, from the Q2'26 release onward | The +8.507% organic demonstrated CAGR. The -1.1pp figure had been… | Neither leg of the condition opposite is met at this date | Base business (excluding Nevro) net sales growth below +6.2% YoY for two consecutive quarters |
| quarterly, from Q2'26 | The 20.0% terminal margin bridge; the step-up burn-off is complete… | GAAP operating margin at or above 15.0% in any quarter, absent a separately disclosed one-time charge | GAAP operating margin below 15.0% in any quarter, absent a separately disclosed one-time charge |
| rolling TTM, tested each quarter | TTM free cash flow margin below 12.0% | TTM free cash flow margin at or above 12.0% | TTM free cash flow margin below 12.0% |
| quarterly, from Q2'26 | The share-gain mechanism; US Spine has printed ~10% for three… | Neither leg of the condition opposite is met at this date | US Spine net sales growth below +3.0% YoY for two consecutive quarters |
NAMED CAUSE, not a valuation bear case. The organic acceleration is NuVasive-disruption RECAPTURE, not durable share gain: GMED's 2024 organic decline was self-inflicted integration disruption, and recovering lost territory produces a 12-18 month growth bulge that ends when the territory is recovered. The evidence for the mechanism: Q1'26's +13.2% organic sits on a Q1'25 comp of -1.4%, so the two-year organic stack is only +5.65% annualised, and FY2025 base-business growth was +5.0%. When recapture completes, organic reverts toward that ~5% while Nevro - spinal cord stimulation, a structurally contracting category against Medtronic, Abbott and Boston Scientific - continues to shrink.
Estimated probability 20%, against the 24% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit when forward expected return falls to zero or below NET OF COSTS - there is no percentage hurdle and none may be reintroduced (the 4.7% cash hurdle was retired 28 July 2026 for producing 0 longs across 22 names). On approach to the $94.50 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | NAMED CAUSE, not a valuation bear case. |
| Momentum | Not determined | 12-1 momentum, 3 August 2025 close $52.63 -> 3 July 2026 close $80.09, Alpaca fully-adjusted. Assessed CROSS-SECTIONALLY: +52.18% against SPY's +21.14%, i.e. +31.0pp of relative strength. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +2.3 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: NAMED CAUSE, not a valuation bear case. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $71.69, which forces an immediate review.